Human natural killer cell development and biology

Sherif Farag, Michael A. Caligiuri

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

Natural killer cells are important innate immune effector cells with potentially broad applications in the treatment of human malignancy due to their ability to lyse neoplastic cells without the need for tumor-specific antigen recognition. Human NK cells can be divided into two functional subsets based on their surface expression of CD56; CD56bright immunoregulatory cells and CD56dim cytotoxic cells. In addition to functional differences, these NK cell subsets can be modulated differently by interleukin (IL)-2, which has permitted the development of lower dose, better tolerated IL-2 regimens for the in vivo expansion and activation of NK cells. The importance of early hematopoietic growth factors, such as c-kit ligand and flt-3 ligand, and their synergy with IL-15 in the development of human NK cells in the bone marrow has permitted the investigation of novel cytokine combinations for optimizing in vivo expansion of NK cell in the clinic. The importance of lymph nodes as a site for NK cell development has recently been elucidated. Furthermore, progress in the field of how NK cell recognize target cells via activating and inhibitory receptors, and how the balance of signals from these receptors can modulate NK cell activity has revolutionized our understanding of the selective killing of tumor cells by NK cells while sparing normal cells. In this review, we summarize current understanding of NK cell biology, and highlight how such knowledge may be translated to optimize the efficacy of using autologous or allogeneic NK cell for the immunotherapy of cancer.

Original languageEnglish (US)
Pages (from-to)123-137
Number of pages15
JournalBlood Reviews
Volume20
Issue number3
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Natural Killer Cells
Cell Biology
Interleukin-2
Interleukin-15
Neoplasms
Stem Cell Factor
Aptitude
Human Development
Neoplasm Antigens
Immunotherapy
Intercellular Signaling Peptides and Proteins
Lymph Nodes
Bone Marrow
Cytokines

Keywords

  • Development
  • KIR
  • Natural killer cell
  • Receptors

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Human natural killer cell development and biology. / Farag, Sherif; Caligiuri, Michael A.

In: Blood Reviews, Vol. 20, No. 3, 05.2006, p. 123-137.

Research output: Contribution to journalArticle

Farag, Sherif ; Caligiuri, Michael A. / Human natural killer cell development and biology. In: Blood Reviews. 2006 ; Vol. 20, No. 3. pp. 123-137.
@article{1c515f742e6041a3a219ca931d14fc5a,
title = "Human natural killer cell development and biology",
abstract = "Natural killer cells are important innate immune effector cells with potentially broad applications in the treatment of human malignancy due to their ability to lyse neoplastic cells without the need for tumor-specific antigen recognition. Human NK cells can be divided into two functional subsets based on their surface expression of CD56; CD56bright immunoregulatory cells and CD56dim cytotoxic cells. In addition to functional differences, these NK cell subsets can be modulated differently by interleukin (IL)-2, which has permitted the development of lower dose, better tolerated IL-2 regimens for the in vivo expansion and activation of NK cells. The importance of early hematopoietic growth factors, such as c-kit ligand and flt-3 ligand, and their synergy with IL-15 in the development of human NK cells in the bone marrow has permitted the investigation of novel cytokine combinations for optimizing in vivo expansion of NK cell in the clinic. The importance of lymph nodes as a site for NK cell development has recently been elucidated. Furthermore, progress in the field of how NK cell recognize target cells via activating and inhibitory receptors, and how the balance of signals from these receptors can modulate NK cell activity has revolutionized our understanding of the selective killing of tumor cells by NK cells while sparing normal cells. In this review, we summarize current understanding of NK cell biology, and highlight how such knowledge may be translated to optimize the efficacy of using autologous or allogeneic NK cell for the immunotherapy of cancer.",
keywords = "Development, KIR, Natural killer cell, Receptors",
author = "Sherif Farag and Caligiuri, {Michael A.}",
year = "2006",
month = "5",
doi = "10.1016/j.blre.2005.10.001",
language = "English (US)",
volume = "20",
pages = "123--137",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Human natural killer cell development and biology

AU - Farag, Sherif

AU - Caligiuri, Michael A.

PY - 2006/5

Y1 - 2006/5

N2 - Natural killer cells are important innate immune effector cells with potentially broad applications in the treatment of human malignancy due to their ability to lyse neoplastic cells without the need for tumor-specific antigen recognition. Human NK cells can be divided into two functional subsets based on their surface expression of CD56; CD56bright immunoregulatory cells and CD56dim cytotoxic cells. In addition to functional differences, these NK cell subsets can be modulated differently by interleukin (IL)-2, which has permitted the development of lower dose, better tolerated IL-2 regimens for the in vivo expansion and activation of NK cells. The importance of early hematopoietic growth factors, such as c-kit ligand and flt-3 ligand, and their synergy with IL-15 in the development of human NK cells in the bone marrow has permitted the investigation of novel cytokine combinations for optimizing in vivo expansion of NK cell in the clinic. The importance of lymph nodes as a site for NK cell development has recently been elucidated. Furthermore, progress in the field of how NK cell recognize target cells via activating and inhibitory receptors, and how the balance of signals from these receptors can modulate NK cell activity has revolutionized our understanding of the selective killing of tumor cells by NK cells while sparing normal cells. In this review, we summarize current understanding of NK cell biology, and highlight how such knowledge may be translated to optimize the efficacy of using autologous or allogeneic NK cell for the immunotherapy of cancer.

AB - Natural killer cells are important innate immune effector cells with potentially broad applications in the treatment of human malignancy due to their ability to lyse neoplastic cells without the need for tumor-specific antigen recognition. Human NK cells can be divided into two functional subsets based on their surface expression of CD56; CD56bright immunoregulatory cells and CD56dim cytotoxic cells. In addition to functional differences, these NK cell subsets can be modulated differently by interleukin (IL)-2, which has permitted the development of lower dose, better tolerated IL-2 regimens for the in vivo expansion and activation of NK cells. The importance of early hematopoietic growth factors, such as c-kit ligand and flt-3 ligand, and their synergy with IL-15 in the development of human NK cells in the bone marrow has permitted the investigation of novel cytokine combinations for optimizing in vivo expansion of NK cell in the clinic. The importance of lymph nodes as a site for NK cell development has recently been elucidated. Furthermore, progress in the field of how NK cell recognize target cells via activating and inhibitory receptors, and how the balance of signals from these receptors can modulate NK cell activity has revolutionized our understanding of the selective killing of tumor cells by NK cells while sparing normal cells. In this review, we summarize current understanding of NK cell biology, and highlight how such knowledge may be translated to optimize the efficacy of using autologous or allogeneic NK cell for the immunotherapy of cancer.

KW - Development

KW - KIR

KW - Natural killer cell

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=33646877669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646877669&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2005.10.001

DO - 10.1016/j.blre.2005.10.001

M3 - Article

C2 - 16364519

AN - SCOPUS:33646877669

VL - 20

SP - 123

EP - 137

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 3

ER -